Industry group’s first technology standard to make it easier for healthcare professionals to access online content
Align Biopharma, a life sciences industry standards group, has made its first technology standard available for industrywide review and input.
This identity management standard identifies individuals in the healthcare professionals (HCPs) system and controls their access to resources.
The goal of the standard is to improve the HCPs experience in accessing information and online content across various websites, portals, virtual events, or webinars for all life sciences companies.The aim is to enable a single sign-on service for HCPs.
To reach this aim, solutions should follow technical requirements for registration, verification and authentication processes. These are defined by a cross-functional team of domain experts.
Align Biopharma is soliciting public review and input for its identity management standard from 9 June on its website. The company will make the final standard available in that summer.
While its first standard is under public review, Align Biopharma will begin development of its second standard for consent and preference management.
The consent and preference management standard will enable consistency in how HCPs specify communication preferences with each life sciences company.Align Biopharma expands members
Align Biopharma added two new members to the group, including Eli Lilly and Company; the group now now includes eight top global pharma companies.
The group expects to continue to expand its membership as more companies dedicate resources to helping HCPs work with life sciences companies.
“Align Biopharma represents our collective commitment to simplify how healthcare professionals get the drug and treatment information they need to deliver care to patients,” said Jennifer Oleksiw, Vice President and Information Officer at Lilly.New President
In addition to its new members, Align Biopharma named Henry Levy as President. Levy has nearly 25 years of experience transforming the way the biopharmaceutical industry improves patient health.
He currently serves as Chief Strategy Officer at Veeva Systems where he represents the company in various industry collaborations.
Previously, he was chief commercial officer at PPD, one of the world’s largest CROs, and head of Accenture’s global life sciences R and D practice.
“There is significant potential for life sciences companies to use digital technology to improve patient engagement by getting timely, tailored treatment information to healthcare professionals,” said Levy.